

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
<i>SP</i>	*	08/878,640	06/19/97	Ludwig et al.			
	*	09/205,520	12/03/99	Sullenger et al.			
	*	09/476,387	12/30/99	Beigelman et al.			
	*	09/870,161	05/29/01	Pavco et al.			
	*	09/877,526	06/08/01	Usman et al.			
	*	09/918,728	07/31/01	Beigelman et al.			
	*	60/082,404	04/20/98	Thompson et al.			
	*	60/101,174	09/21/98	Hartmann et al.			
	*	US 2003/0190635	10/2003	McSwiggen et al.			
<i>SP</i>	*	US 2003/0206887	11/2003	Morrissey et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>SP</i>	*	4,987,071	01/22/91	Cech et al.			
<i>SP</i>	*	5,270,163	12/14/93	Gold et al.			

EXAMINER

Qua C. Hill

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

1635

<i>26</i>	*	5,334,711	08/02/94	Sproat et al.			
	*	5,475,096	12/12/95	Gold et al.			
	*	5,525,468	06/11/96	McSwiggen et al.			
	*	5,589,332	12/31/96	Shih et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,633,133	05/27/97	Long et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,741,679	04/21/98	George et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,807,718	09/15/98	Joyce et al.			
	*	5,814,620	09/29/98	Robinson et al.			
	*	5,834,186	11/10/98	George et al.			
	*	5,849,902	12/15/98	Arrow et al.			
	*	5,854,038	12/29/98	Sullenger and Cech			
<i>28</i>	*	5,871,914	02/16/99	Nathan et al.			

EXAMINER

Anna C. Hill

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

1635

<i>Self</i>	*	5,898,031	04/27/99	Crooke			
	*	5,989,912	11/23/99	Arrow et al.			
	*	5,998,203	12/1999	Matulic-Adamic et al.			
	*	6,001,311	12/14/99	Brennan et al.			
	*	6,005,087	12/21/99	Cook et al.			
	*	6,107,094	08/22/00	Crooke			
	*	6,127,173	10/03/00	Eckstein et al.			
	*	6,159,714	12/12/00	Usman et al.			
	*	6,180,613	01/30/01	Kaplitt et al.			
	*	6,300,074	10/09/01	Gold et al.			
	*	6,346,398	02/12/2	Pavco et al.			
	*	6,476,205	11/05/02	Buhr et al.			
	*	6,482,932	11/19/02	Beigelman et al.			
<i>Self</i>	*	6,506,559	01/14/03	Fire et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>Self</i>								

EXAMINER

Jana C. Hall

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

1635

24	*	2,359,180	08/03/00	CA (Kreutzer et al.)				
	*	1 325 955	07/09/03	EP (Klippel-Giese et al.)				
	*	08208687	08/1996	JP (Hotoda et al.)				
	*	90/14090	05/19/89	WO (Gillespie et al.)				
	*	94/01550	01/20/94	WO (Agrawal et al.)				
	*	97/21808	06/19/97	WO (Robinson)				
	*	99/49029	09/30/99	WO (Graham et al.)				
	*	99/53050	10/21/99	WO (Waterhouse et al.)				
	*	99/61631	12/02/99	WO (Heifetz et al.)				
	*	00/49035	08/24/00	WO (Sheen)				
	*	00/63364	10/26/00	WO (Pachuk et al.)				
	*	01/097850	12/27/01	WO (Siemeister et al.)				
	*	01/96584	12/20/01	WO (Mushegian et al.)				
	*	02/07747	01/31/02	WO (King)				
	*	02/096927	12/05/02	WO (Escobedo et al.)				
	*	02/10378	02/07/02	WO (Cowser et al.)				
	*	02/22636	03/21/02	WO (Bennett et al.)				
24	*	03/068797	08/21/03	WO (Rossi et al.)				

EXAMINER

Paul C. JAL

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

1635

SP	*	03/070887	08/28/03	WO (McSwiggen et al.)				
	*	03/070896	08/28/03	WO (McSwiggen et al.)				
	*	03/070910	08/28/03	WO (McSwiggen et al.)				
	*	03/074654	09/12/03	WO (McSwiggen et al.)				
	*	03/080638	10/02/03	WO (Lacasse et al.)				
	*	04/009769	01/29/04	WO (Tolentino et al.)				
	*	04/043977	05/27/04	WO (Prakush et al.)				
SP	*	04/072261	08/26/04	WO (Li et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

SP	*	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
	*	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
	*	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
	*	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
	*	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
SP	*	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)

EXAMINER

Shera C. [Signature]

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1735-B(400/140)

Serial No.

10/726,236

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

December 2, 2003

Group:

1635

<i>24</i>	*	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999)
	*	International Search Report for PCT/US03/05022 mailed January 6, 2005
	*	International Search Report for PCT/US03/05028 mailed October 17, 2003
	*	International Search Report for PCT/US03/05346 mailed October 17, 2003
	*	International Search Report for PCT/US2004/016390 mailed March 31, 2005
	*	International Search Report for PCT/US2004/027403 mailed July 12, 2005
	*	International Search Report for PCT/US2004/30488 mailed January 12, 2005
	*	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
	*	Kuwabara et al., "A <i>C. elegans</i> patched gene, <i>ptc-1</i> , functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)
	*	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
	*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
	*	Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
	*	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF and VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, S4-S5 (2003)
	*	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
	*	Sharp et al., "RNAi and double-strand RNA," <i>Genes & Development</i> , 13:139-141 (1999)
<i>24</i>	*	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i>]

EXAMINER

Lisa C. Hill

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 01-1735-B(400/140)	Serial No. 10/726,236
	Applicant: Lockridge et al.	
	Filing Date: December 2, 2003	Group: 1635

JLH	*	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," Molecular Interventions, 295, 3, 158-167 (2002)
JLH	*	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," Genes & Development 13:3191-3197 (1999)
JLH	*	Tuschl, "RNA Interference and Small Interfering RNAs," Chembiochem 2:239-245 (2001)
JLH	*	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," Proc. Natl. Acad. Sci. USA, 95, 13959-13964 (1998)

EXAMINER <i>John C. Hill</i>	DATE CONSIDERED <i>3/10/06</i>
-------------------------------------	---------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			16/726, 236
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							Yes	No
<input checked="" type="checkbox"/>	*	EP 0 360 257	03/28/90	EP (Hampel et al.)				
<input checked="" type="checkbox"/>	*	WO 89/02439	03/23/89	WO (Arnold et al.)				
<input checked="" type="checkbox"/>	*	WO 91/03162	03/21/91	WO (Rossi et al.)				
<input checked="" type="checkbox"/>	*	WO 92/07065	04/30/92	WO (Eckstein et al.)				
<input checked="" type="checkbox"/>	*	WO 93/15187	08/05/93	WO (Usman et al.)				
<input checked="" type="checkbox"/>	*	WO 93/23057	11/25/93	WO (Thompson et al.)				
<input checked="" type="checkbox"/>	*	WO 93/23569	11/25/93	WO (Draper et al.)				
<input checked="" type="checkbox"/>	*	WO 94/02595	02/03/94	WO (Sullivan et al.)				
<input checked="" type="checkbox"/>	1.	WO 94/11499	05/26/94	WO (Ullrich et al.)				
<input checked="" type="checkbox"/>	2.	WO 94/21791	09/29/94	WO (Bergmann et al.)				
<input checked="" type="checkbox"/>	*	WO 95/04142	02/09/95	WO (Robinson et al.)				
<input checked="" type="checkbox"/>	*	WO 95/04818	02/16/95	WO (Draper et al.)				
<input checked="" type="checkbox"/>	*	WO 95/06731	03/09/95	WO (Usman et al.)				
<input checked="" type="checkbox"/>	*	WO 95/11304	04/27/95	WO (Usman et al.)				

EXAMINER <i>Lisa C. [Signature]</i>	DATE CONSIDERED 3/10/06
---	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

MBHB01,1735-B
(400.140)

Serial N .

TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

10/726,236

Applicant:

Lockridge et al.

Filing Date:

TBA
12/2/03

Group:

TBA
1635

30	*	WO 95/11910	05/04/95	WO (Dudycz et al.)				
	*	WO 95/13380	05/18/95	WO (Draper et al.)				
	*	WO 95/21868	08/17/95	WO (Rockwell and Goldstein)				
	*	WO 95/23225	08/31/95	WO (Stinchcomb et al.)				
	*	WO 96/10390	04/11/96	WO (Ansell et al.)				
	*	WO 96/10391	04/11/96	WO (Choi et al.)				
	*	WO 96/10392	04/11/96	WO (Holland et al.)				
	*	WO 96/18736	06/20/96	WO (Beigelman et al.)				
	*	WO 96/22689	08/01/96	WO (Pyle et al.)				
	3.	WO 97/00957	01/09/97	WO (Patterson-Winston et al.)				
	*	WO 97/15662	05/01/97	WO (Pavco et al.)				
	*	WO 97/26270	07/24/97	WO (Wincott et al.)				
	*	WO 98/13526	04/02/98	WO (Woolf et al.)				
	*	WO 98/27104	06/25/98	WO (Breaker et al.)				
	*	WO 98/28317	07/02/98	WO (Matulic-Adamic)				
	*	WO 98/43993	10/08/98	WO (Breaker et al.)				
	*	WO 98/58058	12/23/98	WO (Ludwig et al.)				
24	*	WO 99/04819	02/04/99	WO (Klimuk et al.)				

EXAMINER

Ann C. Hill

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		10/726, 236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

<i>28</i>	*	WO 99/05094	02/04/99	WO (Beigelman et al.)				
	*	WO 99/07409	02/18/99	WO (Deschamps-Depaillette)				
	*	WO 99/14226	03/25/99	WO (Wengel et al.)				
	*	WO 99/16871	04/08/99	WO (Eckstein et al.)				
	*	WO 99/32619	07/01/99	WO (Fire et al.)				
	*	WO 99/54459	10/28/99	WO (Thompson et al.)				
	*	WO 99/55857	11/04/99	WO (Beigelman et al.)				
	*	WO 99/63116	12/09/99	WO (Storella et al.)				
	*	WO 00/01846	01/13/00	WO (Plaetinck et al.)				
	*	WO 00/24931	05/04/00	WO (Nathan and Ellington)				
	*	WO 00/26226	05/11/00	WO (Breaker et al.)				
	*	WO 00/44895	08/03/00	WO (Kreutzer et al.)				
	*	WO 00/44914	08/03/00	WO (Li et al.)				
	*	WO 00/66604	11/09/00	WO (Wengel et al.)				
	*	WO 00/73416	12/07/00	WO (Labarbera et al.)				
	*	WO 01/29058	04/26/01	WO (Mello and Fire)				
	*	WO 01/32920	05/10/01	WO (Pappa)				
<i>28</i>	*	WO 01/36646	05/25/01	WO (Zernicka-Goetz et al.)				

EXAMINER <i>Qua C. Hill</i>	DATE CONSIDERED 3/10/06
---------------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	MBHB01,1735-B (400.140)	TBA
	Applicant: Lockridge et al.	
	Filing Date: TBA 12/2/03	Group: TBA 1635

JCH	*	WO 01/75164	10/11/01	WO (Tuschl et al.)				
-----	---	-------------	----------	--------------------	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

JCH	*	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," <u>Science</u> 271:1410-1413 (1996)
	*	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <u>Trends Cell Biol.</u> 2:139-144 (1992)
	*	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <u>Nucleic Acids Research</u> 26:4910-4916 (1998)
	*	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <u>Biochemistry</u> 34:6504-6512 (1995)
	*	Bartel and Szostak, "Isolation of New Ribozymes from a Large Pool of Random Sequences," <u>Science</u> 261:1411-1418 (1993)
	*	Bass, "The short answer," <u>Nature</u> 411:428-429 (2001)
	*	Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <u>Tetrahedron</u> 49:1925-1963 (1993)
	*	Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," <u>Science</u> 257:635-641 (1992)
	*	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <u>The Journal of Biological Chemistry</u> 270:25702-25708 (1995)
	*	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <u>Nucleosides & Nucleotides</u> 16:951-954 (1997)
JCH	*	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <u>Bioconjugate Chem.</u> 8:204-212 (1997)

EXAMINER JCH C. JCH	DATE CONSIDERED 3/10/06
-------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		MBHB01,1735-B (400.140)	TBA 10/726,236	
		Applicant: Lockridge et al.		
		Filing Date: TBA 12/2/03	Group: TBA 1635	

28	*	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <i>EBMO J.</i> 12:2567-2574 (1993)
	*	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," <i>Genes & Development</i> 6:129-134 (1992)
	*	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the <i>Tetrahymena</i> Ribozyme," <i>Biochemistry</i> 35:648-568 (1996)
	*	Blesch, "Delivery of Neurotrophic Factors to Neuronal Targets: Toward Gene Therapy in the CNS," <i>Drug News & Perspectives</i> 13:269-280 (2000)
	*	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
	*	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)
	*	Breaker et al., "A DNA enzyme with Mg ²⁺ -dependent RNA phosphoesterase activity," <i>Chemistry & Biology</i> 2(10):655-660 (1995)
	*	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
	*	Breaker, "Catalytic DNA: in training and seeking employment," <i>Nature Biotechnology</i> 17:422-423 (1999)
	*	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
29	*	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)

EXAMINER Lisa C. Hill	DATE CONSIDERED 3/10/06
---------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		MBHB01,1735-B (400.140)	TBA			
(Use several sheets if necessary)		Applicant: Lockridge et al.				
Filing Date:		Group:				
TBA 12/2/03		TBA 1635				

Self	*	Brognez et al., "Fluorescence of Experimented Endometriosis in Rabbits, Using Tamoxifen-eosin Association," <u>Human Reproduction</u> 10:927-931 (1995)
	*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <u>Biochemistry</u> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
	*	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <u>Bioorganic & Medicinal Chemistry</u> 5:1999-2010 (1997)
	*	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <u>Methods in Enzymology</u> 211:3-19 (1992)
	*	Cech, "Ribozymes and Their Medical Implications," <u>JAMA</u> 260:3030-3034 (1988)
	*	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <u>Nucleic Acids Research</u> 23(20):4092-4096 (1995)
	*	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <u>Nucleic Acids Research</u> 20:4581-4589 (1992)
	*	Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <u>J. Biol. Chem.</u> 269:25856-25864 (1994)
	*	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," <u>Nature</u> 354:320-322 (1991)
	*	Christoffersen and Marr, "Ribozymes as Human Therapeutic Agents," <u>J. Med. Chem.</u> 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
	*	Christoffersen et al., "Application of computational technologies to ribozyme biotechnology products," <u>Journal of Molecular Structure (Theochem)</u> 311:273-284 (1994) (maybe referred to as Christofferson)
Self	*	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <u>J. Am. Chem. Soc.</u> 113:6324-6326 (1991)

EXAMINER Sue C. Hill	DATE CONSIDERED 3/10/06
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		10/726,236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

Ref	*	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From <i>Neurospora</i> VS RNA," <u>Biochemistry</u> 32:2795-2799 (1993)
	*	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <u>Trends In Genetics</u> 12:510-515 (1996)
	*	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <u>Advances in Pharmacology</u> 40:1-49 (1997)
	*	Crooke, "Antisense Therapeutics," <u>Biotechnology and Genetic Engineering Reviews</u> 15:121-157 (1998)
	*	Crooke, "Progress in Antisense Technology: The End of the Beginning," <u>Methods in Enzymology</u> 313:3-45 (1999)
	*	Cummings and Metcalf, "Effect of Surgically Induced Endometriosis on Pregnancy and Effect of Pregnancy and Lactation on Endometriosis in Mice ¹ " <u>P.S.E.B.M.</u> 212:332-337 (1996)
	*	Cummings et al., "Promotion of Endometriosis by 2,3, 7, 8-Tetrachlorodibenzo- <i>p</i> -dioxin in Rats and Mice: Time-Dose Dependence and Species Comparison ^{1,2} " <u>Toxicology and Applied Pharmacology</u> 138:131-139 (1996)
	*	D'Hooghe et al., "The Cycle Pregnancy Rate is Normal in Baboons with Stage I Endometriosis but Decreased in Primates with Stage II and Stage III-IV Disease," <u>Fertility and Sterility</u> 66:809-813 (1996)
	*	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of <i>in Vitro</i> Reaction Rates and Products," <u>J. Mol. Biol.</u> 256:31-49 (1996)
	*	Delihias et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <u>Nature Biotechnology</u> 15:751-753 (1997)
Ref	*	Donnez et al., "Vascular Endothelial Growth Factor (VEGF) in Endometriosis," <u>Human Reproduction</u> 13:1686-1690 (1998)

EXAMINER Anna C. Hall	DATE CONSIDERED 3/10/06
---------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
			MBHB01,1735-B (400.140)	TBA
			10/726,236	
			Applicant: Lockridge et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	(Use several sheets if necessary)		Filing Date:	Group:
			TBA 12/2/03	TBA 1635

<i>Set</i>	*	Dreyfus, "Restriction Ribozymes?" <u>Einstein Quarterly Journal of Biology and Medicine</u> 6:92-93 (1988)
	*	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <u>Journal of Virology</u> 66:1432-1441 (1992)
	*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <u>Nucleic Acids Research</u> 18:6353-6359 (1990)
	*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <u>Nucleic Acids Research</u> 18:6353-6359 (1990)
	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <u>Proc. Natl. Acad. Sci. USA</u> 89:504-508 (1992)
	*	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <u>Biopolymers</u> 48:39-55 (1998)
	*	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <u>Nature</u> 365:566-568 (1993)
	*	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <u>Nature</u> 411:494-498 (2001)
	*	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	*	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)
	*	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)
<i>Set</i>	*	Fasciani et al., "High Concentrations of the Vascular Endothelial Growth Factor and Interleukin-8 in Ovarian Endometriomata," <u>Molecular Human Reproduction</u> 6:50-54 (2000)

EXAMINER <i>Qua C. Hill</i>	DATE CONSIDERED 3/10/06
---------------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		MBHB01,1735-B (400.140)	TBA
		Applicant: Lockridge et al.	
		Filing Date:	Group:
		TBA 12/2/03	TBA 1635

✓	*	Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," <u>Gene</u> 82:53-61 (1989)
	*	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)
	*	Ferrara, "Vascular Endothelial Growth Factor," <u>Trends Cardiovasc Med</u> 3:244-250 (1993)
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <u>Science</u> 249:783-786 (1990)
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <u>Science</u> 249:783-786 (1990)
	*	Fox, "Targeting DNA with Triplexes," <u>Current Medicinal Chemistry</u> 7:17-37 (2000)
	*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <u>Proc. Natl. Acad. Sci. USA</u> 83:9373-9377 (1986) [sometimes referred to as Frier]
	*	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u> 21:2867-2872 (1993)
	*	Genbank Accession No. NM_002019
	*	Genbank Accession No. NM_002253
	*	Genbank Assession No. NM_003376
	*	Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-associated Heparin-like Molecules," <u>The Journal of Biological Chemistry</u> 267:6093-6098 (1992)
	*	Gold et al., "Diversity of Oligonucleotide Functions," <u>Annu. Rev. Biochem.</u> 64:763-797 (1995)
✓	*	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <u>Neuroscience</u> 76:1153-1158 (1997)

EXAMINER	John C. [Signature]	DATE CONSIDERED	3/10/06
----------	---------------------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		10/726,236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

24	*	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <u>Gene Therapy</u> 4:45-54 (1997)
	*	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," <u>Biochemistry</u> 34:4068-4076 (1995)
	*	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <u>Chemistry & Biology</u> 2:761-770 (1995)
	*	Groothuis and Levy, "The entry of antiviral and antiretroviral drugs into the central nervous system," <u>Journal of NeuroVirology</u> 3:387-400 (1997)
	*	Guerrier-Takada et al., "Metal Ion Requirements and Other Aspects of the Reaction Catalyzed by M1 RNA, the RNA Subunit of Ribonuclease P from <i>Escherichia coli</i> ," <u>Biochemistry</u> 25:1509-1515 (1986)
	*	Guo and Collins, "Efficient <i>trans</i> -cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <u>EMBO J.</u> 14:368-376 (1995)
	*	Hagihara et al., "Widespread gene transfection into the central nervous system of primates," <u>Gene Therapy</u> 7:759-763 (2000)
	*	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <u>Antisense & Nucleic Acid Drug Development</u> 9:25-31 (1999)
	*	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," <u>Biochemistry</u> 28:4929-4933 (1989)
	*	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," <u>Nucleic Acids Research</u> 18:299-304 (1990)
	*	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," <u>RNA</u> 1:210-218 (1995)
26	*	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," <u>Gene</u> 82:43-52 (1989)

EXAMINER Don C. Hill	DATE CONSIDERED 3/10/06
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

MBHB01,1735-B
(400.140)

Serial No.

TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

TBA
12/2/03

Group:

TBA
1635

20	*	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," <i>Nature</i> 334:585-591 (1988)
	*	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," <i>Biochemistry</i> 34:15813-15828 (1995)
	*	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <i>Science</i> 287:820-825 (2000)
	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," <i>Biochemistry</i> 29:10159-10171 (1990)
	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," <i>Biochemistry</i> 29:10172-10180 (1990)
	*	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," <i>Biochemistry</i> 33:3374-3385 (1994)
	*	Hertel et al., "Numbering System for the Hammerhead," <i>Nucleic Acids Research</i> 20:3252 (1992)
	*	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," <i>VCH</i> , 331-417
	*	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <i>Chem. Pharm. Bull.</i> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	*	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <i>Biochemical and Biophysical Research Communication</i> 214(2):403-409 (1995)
	*	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <i>Science</i> 229:345-352 (1985)
24	*	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," <i>Proc. Natl. Acad. Sci. USA</i> 86:7706-7710 (1989)

EXAMINER

Anna C. Hill

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		10/726,236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

SLF	*	Jarvis et al., "Optimizing the Cell Efficacy of Synthetic Ribozymes," <u>Journal of Biological Chemistry</u> 271:29107-29112 (1996)
	*	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993)
	*	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <u>Clinical Chemistry</u> 45:1628-1650 (1999)
	*	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," <u>Nucleic Acids Research</u> 17:1371-1377 (1989) (also referred to as Jefferies)
	*	Jellinek et al., "Inhibitions of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)
	*	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
	*	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," <u>Genes & Development</u> 7:130-138 (1993)
	*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)
	*	Joyce, "Directed Molecular Evolution," <u>Scientific American</u> 267:90-97 (1992)
	*	Karpeisky et al., "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
	*	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <u>Antisense Research & Development</u> 2:3-15 (1992)
	*	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of <i>Tetrahymena</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 84:8788-8792 (1987)
	*	Knitt et al., "ph Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconventional Origin of an Apparent pK _a ," <u>Biochemistry</u> 35:1560-1570 (1996)
	*	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule," <u>Nucleic Acids Research</u> , 26(18):4116-4120 (1998).
SLF	*	Kumar and Ellington, "Artificial evolution and natural ribozymes," <u>FASEB J.</u> 9:1183-1195 (1995)

EXAMINER [Signature]	DATE CONSIDERED 3/10/06
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA 10/726,236
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635


SLY	*	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)
	*	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
	*	Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
	*	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <i>EMBO J.</i> 11:4411-4418 (1992)
	*	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size," <i>Nucleic Acids Research</i> 24:835-842 (1996)
	*	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," <i>Biochemistry</i> 34:14394-14399 (1995)
	*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <i>Methods Enzymol.</i> 217:47-66 (1993)
	*	Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
	*	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)
	*	Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," <i>J. Mol. Biol.</i> 235:1206-1217 (1994)
	*	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
SLY	*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <i>Proc. Natl. Acad. Sci. USA</i> 91:6977-6981 (1994)

EXAMINER <i>Don C. Hill</i>	DATE CONSIDERED 3/10/06
--------------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) <p style="text-align: center;">U.S. Department of Commerce Patent and Trad mark Office</p> <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(Use several sheets if necessary)</p>	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA 10/726,236
	Applicant: Lockridge et al.	
	Filing Date: TBA 12/2/03	Group: TBA 1635

2001	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <u>Nucleic Acids Research</u> 21:2585-2589 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <u>Biochemistry</u> 32:1751-1758 (1993)
	*	Maher et al., "Kinetic Analysis of Oligodeoxyribonucleotide-Directed Triple-Helix Formation on DNA," <u>Biochemistry</u> 29:8820-8826 (1990)
	*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <u>Cell</u> , 110, 563-574 (2002)
	*	Matthews et al., "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to <i>c-kit</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 88:9026-9030 (1991)
	*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <u>Nucleosides & Nucleotides</u> 10:287-290 (1991)
	*	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> 83:399-403 (1986)
	*	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," <u>RNA</u> 2:395-403 (1996)
	*	McLaren et al., "Vascular Endothelial Growth Factor Is Produced by Peritoneal Fluid Macrophages in Endometriosis and is Regulated by Ovarian Steroids," <u>J. Clin. Invest.</u> , 98, 482-489 (1996)
	*	McLaren, "Vascular Endothelial Growth Factor and Endometriotic Angiogenesis," <u>Human Reproduction Update</u> 6:45-55 (2000)
	*	McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," <u>Human Reproduction</u> 11:220-223 (1996)
2004	*	Mesmaeker et al., "Novel Backbone Replacements for Oligonucleotides," <u>American Chemical Society</u> , pp. 24-39 (1994)

EXAMINER 	DATE CONSIDERED 3/10/06
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		10/726,236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

Self	*	Michel and Westhof, "Slippery substrates," <u>Nat. Struct. Biol.</u> 1:5-7 (1994)
	*	Michel et al., "Structure and Activities of Group II Introns," <u>Annu. Rev. Biochem.</u> 64:435-461 (1995)
	*	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <u>Biochemistry</u> 34:2965-2977 (1995)
	*	Millauer, "High Affintiy VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993)
	*	Milligan and Uhlenbeck, "Synthesis of Small RNAs Using T7 RNA Polymerase," <u>Methods Enzymol.</u> 180:51-62 (1989)
	*	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," <u>Nature Biotechnology</u> 15:537-541 (1997)
	*	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic plants," <u>Proc. Natl. Acad. Sci. USA</u> 93:6780-6785 (1996)
	*	Mohr et al., "A tyrosyl-tRNA synthetase can function similarly to an RNA structure in the <i>Tetrahymena</i> ribozyme," <u>Nature</u> 370:147-150 (1994)
	*	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <u>Science</u> 256:992-996 (1992)
	*	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," <u>Critical Reviews in Oncogenesis</u> 7:151-190 (1996)
	*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <u>Biochemistry</u> 33:1271-1277 (1994)
	*	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <u>Ann. Rev. Biochem.</u> 44:273-293 (1975)
Self	*	Neufeld et al., "Vascular Endothelial Growth Factor and Its Receptors," <u>Progress in Growth Factor Research</u> 5:89-97 (1994)

EXAMINER <i>Dea C. [Signature]</i>	DATE CONSIDERED 3/10/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

MBHB01,1735-B
(400.140)

Serial No.

TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

TBA 12/2/03

Group:

TBA 1635

SP	*	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <u>Nucleic Acids Research</u> 22(14):2830-2836 (1994)
	*	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <u>Nucleic Acids Symp. Ser.</u> 27:15-16 (1992)
	*	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 89:10802-10806 (1992)
	*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <u>Biochimica et Biophysica Acta</u> 1238:86-90 (1995)
	*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <u>Biochemistry</u> 30:9914-9921 (1991)
	*	Orgel, "Selection <i>in vitro</i> ," <u>Proc. R. Soc. London B.</u> 205:435-442 (1979)
	*	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," <u>Proc. Natl. Acad. Sci. USA</u> 92:12510-12514 (1995)
	*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 92:5592-5596 (1995)
	*	Peel and Klein, "Adeno-associated virus vectors: activity and applications in the CNS," <u>Journal of Neuroscience Methods</u> 98:95-104 (2000)
	*	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <u>Nature</u> 344:565-567 (1990) (often mistakenly listed as Perrault)
	*	Perrotta and Been, "A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA," <u>Nature</u> 350:434-436 (1991)
	*	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," <u>Biochemistry</u> 31:16-21 (1992)
SP	*	Peterson et al., "Future Prospects of Gene Therapy for Treating CNS Diseases," <u>Central Nervous System Diseases</u> Chapter 24:485-508 (2000)

EXAMINER

John C. Hill

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

MBHB01,1735-B
(400.140)

Serial No.

TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

TBA
12/2/03

Group:

TBA
1635

LLP	*	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
	*	Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <i>Pharmacol Ther.</i> 78:55-113 (1998)
	*	Plouët et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells," <i>The EMBO Journal</i> 8:3801-3806 (1989)
	*	Praseuth et al., "Triple helix formation and the antigene for sequence-specific control of gene expression," <i>Biochimica et Biophysica Acta</i> 1489:181-206 (1999)
	*	Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," <i>Nucleic Acids Research</i> 21:4253-4258 (1993)
	*	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," <i>Biochemistry</i> 33:2716-2725 (1994)
	*	Quereda et al., "Individual and Combined Effects of Triptoreline and Gestrinone on Experimental Endometriosis in Rats," <i>European Obstetrics & Gynecology and Reproductive Biology</i> 67:35-40 (1996)
	*	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991)
	*	Robertson et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Ribonuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," <i>J. Biol. Chem.</i> 247:5243-5251 (1972)
	*	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," <i>Aids Research and Human Retroviruses</i> 8:183-189 (1992)
	*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <i>Proc. Natl. Acad. Sci. USA</i> 94:4262-4266 (1997)
	*	Santoro et al., "Mechanism and Utility of an RNA-Cleaving DNA Enzyme," <i>Biochemistry</i> 37:13330-13342 (1998)
SLP	*	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <i>J. Am. Chem. Soc.</i> 122:2433-2439 (2000)

EXAMINER

Anna C. Bell

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

MBHB01,1735-B
(400.140)

Serial No.

TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

TBA
12/2/03

Group:

TBA
1635

SP	*	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)
	*	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In <i>Neurospora</i> Mitochondria," <u>Cell</u> 61:685-696 (1990)
	*	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a <i>Neurospora</i> Mitochondrial Plasmid Transcript," <u>Proc. Natl. Acad. Sci. USA</u> 88:8826-8830 (1991)
	*	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
	*	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
	*	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <u>The Journal of Biological Chemistry</u> 274:21783-21789 (1999)
	*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <u>Nucleic Acids Research</u> 24:573-581 (1996)
	*	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <u>Pro. Neuro-Psychopharmacol. & Biol. Psychiat.</u> 23:941-949 (1999) [sometimes cited by RPI as <u>Prog Neuropsychopharmacol Biol Psychiatry</u> 23:941-949, 1999]
	*	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," <u>Cell</u> 81:991-1002 (1995)
	*	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research</u> 15:3113-3129 (1987)
	*	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <u>Nucleic Acids Research</u> 19:4247-4251 (1991)
SP	*	Shalaby et al., "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice," <u>Letters to Nature</u> 376:62-66 (1995)

EXAMINER

Ana C. Zell

DATE CONSIDERED

3/10/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		10 726, 236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

✓	*	Sharkey et al., "Vascular Endothelial Growth Factor Expression in Human Endometrium is Regulated by Hypoxia," <u>The Journal of Clinical Endocrinology & Metabolism</u> 85:402-409 (2000)
	*	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <u>Oncogene</u> 5:519-524 (1990)
	*	Shifren et al., "Ovarian Steroid Regulation of Vascular Endothelial Growth Factor in the Human Endometrium: Implications for Angiogenesis during the Menstrual Cycle and in the Pathogenesis of Endometriosis," <u>The Journal of Clinical Endocrinology & Metabolism</u> 81:3112-3118 (1996)
	*	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <u>J. Clin. Invest.</u> 91:2235-2243 (1993)
	*	Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," <u>Methods in Enzymology</u> 313:522-533 (1999)
	*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <u>Science</u> 261:1004-1288 (1993)
	*	Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <u>Antisense & Nucleic Acid Drug Development</u> 7:151-157 (1997)
	*	Stoeckemann et al., "Effects of the Progesterone Antagonists Onapristone (ZK 98 299) and ZK 136 799 on Surgically Induced Endometriosis in Intact Rats," <u>Human Reproduction</u> 10:3264-3271 (1995)
	*	Strobel and Dervan, "Site-Specific Cleavage of a Yeast Chromosome by Oligonucleotide-Directed Triple-Helix Formation," <u>Science</u> 249:73-75 (1990)
✓	*	Strobel et al., "Exocyclic Amine of the Conserved G-U Pair at the Cleavage Site of the <i>Tetrahymena</i> Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," <u>Biochemistry</u> 35:1201-1211 (1996)

EXAMINER [Signature]	DATE CONSIDERED 3/10/06
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB01,1735-B (400.140)	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		10/126,236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

SEP	*	Strobel et al., "Minor Groove Recognition of the Conserved G-U Pair at the <i>Tetrahymena</i> Ribozyme Reaction Site," <u>Science</u> 267:675-679 (1995)
	*	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <u>Nature</u> 371:619-622 (1994)
	*	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <u>Science</u> 262:1566-1569 (1993)
	*	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," <u>Cell</u> 63:601-608 (1990)
	*	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <u>Current Opinion in Molecular Therapeutics</u> 2:100-105 (2000)
	*	Szostak and Ellington, "Ch. 20 - In Vitro Selection of Functional RNA Sequences," in <u>The RNA World</u> , edited by Gesteland and Atkins, Cold Spring Harbor Laboratory Press, pp. 511-533 (1993)
	*	Szostak, " <i>In Vitro</i> Genes," <u>TIBS</u> 17:89-93 (1993)
	*	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <u>Nucleic Acids Research</u> 19:5125-5130 (1991)
	*	Takeshita et al., "Therapeutic Angiogenesis - A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," <u>J. Clin. Invest.</u> 93:662-670 (1994)
	*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," <u>RNA</u> 3:914-925 (1997)
	*	Terman et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," pp 1677-1683 (1991)
	*	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <u>Nucleic Acids Research</u> 23:2259-2268 (1995)
SEP	*	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <u>Proc. Natl. Acad. Sci. USA</u> 90:1300-1304 (1993)

EXAMINER [Signature]	DATE CONSIDERED 3/10/06
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		MBHB01,1735-B (400.140)	TBA
		10 726,236	
		Applicant: Lockridge et al.	
		Filing Date: TBA 12/2/03	Group: TBA 1635

Self	*	Turner et al., "Improved Parameters for Prediction of RNA Structure," <u>Cold Spring Harbor Symposia on Quantitative Biology</u> Volume LII, pp. 123-133 (1987)
	*	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J. Am. Chem. Soc.</u> 109:3783-3785 (1987)
	*	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <u>Proc. Natl. Acad. Sci. USA</u> 96:7053-7058 (1999)
	*	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <u>FEBS Letters</u> 421:280-284 (1998)
	*	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," <u>Nature</u> 328:596-600 (1987) (this is listed as Nature 327 in the various specifications, but it is actually 328)
	*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)
	*	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," <u>Annual Reports in Medicinal Chemistry</u> 30:285-294 (1995)
	*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
	*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)
	*	Usman et al., "Hammerhead ribozyme engineering," <u>Current Opinion in Structural Biology</u> 1:527-533(1996)
	*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
VA	*	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth," <u>The Journal of Biological Chemistry</u> 265:19461-19466 (1990)

EXAMINER Anna C. [Signature]	DATE CONSIDERED 3/10/06
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

MBHB01,1735-B
(400.140)

Serial No.

TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Lockridge et al.

Filing Date:

TBA
12/2/03

Group:

TBA
1635

✓	*	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u> 21:3249-3255 (1993)
	*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> 67:99-134 (1998)
	*	Warashina, et al., "Extremely High and Specific Activity of DNA Enzymes in Cells with a Philadelphia Chromosome," <u>Chemistry & Biology</u> , 6(4):237-250 (1999)
	*	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 ⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <u>Journal of Virology</u> 65:5531-5534 (1994)
	*	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <u>Nucleic Acids Research</u> 23:2092-2096 (1995)
	*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
	*	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)
	*	Woolf et al., "Specificity of Antisense Oligonucleotides <i>in vivo</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 89:7305-7309 (1992)
	*	Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research," <u>BioPharm</u> pp20-33 (1994)
	*	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344 (1993)
	*	Yuan et al., "Targeted cleavage of mRNA by human RNase P," <u>Proc. Natl. Acad. Sci. USA</u> 89:8006-8010 (1992)
	*	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the <i>Tetrahymena</i> ribozyme," <u>Nucleic Acids Research</u> 24:854-858 (1996)
✓	*	Zaug et al., "The <i>Tetrahymena</i> Ribozyme Acts Like an RNA Restriction Endonuclease," <u>Nature</u> 324:429-433 (1986)

EXAMINER

Lena C. Hill

DATE CONSIDERED






3/10/06


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
			MBHB01,1735-B (400.140)	TBA
			Applicant: Lockridge et al.	
		Filing Date:	Group:	
		TBA 12/2/03	TBA 1635	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

	*	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <u>Mol. Cell. Biol.</u> 10:4529-4537 (1990)
	*	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," <u>Cell</u> 83:529-538 (1995)
	*	Parry et al. 1999. "Bioactivity of anti-angiogenic ribozymes targeting <i>Flt-1</i> and <i>KDR</i> mRNA," <u>Nucleic Acid Res.</u> 27:2569-77.
	4.	International Search Report for PCT/US96/17480, Filed October 25, 1996
	*	International Search Report for PCT/US02/17674, Filed May 29, 2002

EXAMINER 	DATE CONSIDERED 3/10/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.